OBJECTIVES: To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc). METHODS: In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod for 8 weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up for the analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the number of myofibroblasts. The safety of paquinimod was evaluated throughout the study. RESULTS: Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3 mg/day for 8 weeks. After the treatment, a reduction of type I IFN activity in the plasma from one patient with elevated baseline IFN activity was recorded. A trend towards reduced IFN activity in the skin after treatment was also observed in patients. The serum level of CCL2 was reduced in 7 of 9 patients after paquinimod treatment. There was a median reduction of 10% of the number of myofibroblasts in skin biopsies at week 8 compared to baseline. No change in modified Rodnan skin score and quality of life was detected in the study. Reported adverse events (AEs) were mild to moderate and expected with the most common being arthralgia (n = 3) and headache (n = 3), and C-reactive protein (CRP) increase. CONCLUSIONS: Analysis of biomarkers before and after treatment suggest reduced type I IFN activity and reduced number of myofibroblasts in lesional skin. Paquinimod was overall well tolerated with mild to moderate and expected AEs. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01487551 . Registered on 7 September 2011.
OBJECTIVES: To evaluate the changes in disease-related biomarkers and safety of paquinimod, an oral immunomodulatory compound, in patients with systemic sclerosis (SSc). METHODS: In this open-label, single-arm, multicenter study, SSc patients with a rapidly progressive disease received paquinimod for 8 weeks. Blood and skin biopsies were collected at baseline, during treatment, and at follow-up for the analyses of type I interferon (IFN) activity, chemokine (C-C motif) ligand 2 (CCL2), and the number of myofibroblasts. The safety of paquinimod was evaluated throughout the study. RESULTS: Nine SSc patients were enrolled and completed the study treatment with paquinimod at 3 mg/day for 8 weeks. After the treatment, a reduction of type I IFN activity in the plasma from one patient with elevated baseline IFN activity was recorded. A trend towards reduced IFN activity in the skin after treatment was also observed in patients. The serum level of CCL2 was reduced in 7 of 9 patients after paquinimod treatment. There was a median reduction of 10% of the number of myofibroblasts in skin biopsies at week 8 compared to baseline. No change in modified Rodnan skin score and quality of life was detected in the study. Reported adverse events (AEs) were mild to moderate and expected with the most common being arthralgia (n = 3) and headache (n = 3), and C-reactive protein (CRP) increase. CONCLUSIONS: Analysis of biomarkers before and after treatment suggest reduced type I IFN activity and reduced number of myofibroblasts in lesional skin. Paquinimod was overall well tolerated with mild to moderate and expected AEs. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01487551 . Registered on 7 September 2011.
Authors: Zana Brkic; Lenny van Bon; Marta Cossu; Cornelia G van Helden-Meeuwsen; Madelon C Vonk; Hanneke Knaapen; Wim van den Berg; Virgil A Dalm; Paul L Van Daele; Adriana Severino; Naomi I Maria; Samara Guillen; Willem A Dik; Lorenzo Beretta; Marjan A Versnel; Timothy Radstake Journal: Ann Rheum Dis Date: 2015-09-14 Impact factor: 19.103
Authors: Otylia Kowal-Bielecka; Jaap Fransen; Jerome Avouac; Mike Becker; Agnieszka Kulak; Yannick Allanore; Oliver Distler; Philip Clements; Maurizio Cutolo; Laszlo Czirjak; Nemanja Damjanov; Francesco Del Galdo; Christopher P Denton; Jörg H W Distler; Ivan Foeldvari; Kim Figelstone; Marc Frerix; Daniel E Furst; Serena Guiducci; Nicolas Hunzelmann; Dinesh Khanna; Marco Matucci-Cerinic; Ariane L Herrick; Frank van den Hoogen; Jacob M van Laar; Gabriela Riemekasten; Richard Silver; Vanessa Smith; Alberto Sulli; Ingo Tarner; Alan Tyndall; Joep Welling; Frederic Wigley; Gabriele Valentini; Ulrich A Walker; Francesco Zulian; Ulf Müller-Ladner Journal: Ann Rheum Dis Date: 2016-11-09 Impact factor: 19.103
Authors: Jörg H W Distler; Andrea-Hermina Györfi; Meera Ramanujam; Michael L Whitfield; Melanie Königshoff; Robert Lafyatis Journal: Nat Rev Rheumatol Date: 2019-11-11 Impact factor: 20.543
Authors: Jacob M van Laar; Dominique Farge; Jacob K Sont; Kamran Naraghi; Zora Marjanovic; Jérôme Larghero; Annemie J Schuerwegh; Erik W A Marijt; Madelon C Vonk; Anton V Schattenberg; Marco Matucci-Cerinic; Alexandre E Voskuyl; Arjan A van de Loosdrecht; Thomas Daikeler; Ina Kötter; Marc Schmalzing; Thierry Martin; Bruno Lioure; Stefan M Weiner; Alexander Kreuter; Christophe Deligny; Jean-Marc Durand; Paul Emery; Klaus P Machold; Francoise Sarrot-Reynauld; Klaus Warnatz; Daniel F P Adoue; Joël Constans; Hans-Peter Tony; Nicoletta Del Papa; Athanasios Fassas; Andrea Himsel; David Launay; Andrea Lo Monaco; Pierre Philippe; Isabelle Quéré; Éric Rich; Rene Westhovens; Bridget Griffiths; Riccardo Saccardi; Frank H van den Hoogen; Willem E Fibbe; Gérard Socié; Alois Gratwohl; Alan Tyndall Journal: JAMA Date: 2014-06-25 Impact factor: 56.272
Authors: Djúlio C Zanin-Silva; Maynara Santana-Gonçalves; Marianna Y Kawashima-Vasconcelos; João R Lima-Júnior; Juliana B E Dias; Daniela A Moraes; Dimas T Covas; Kelen C R Malmegrim; Leandra Ramalho; Maria Carolina Oliveira Journal: Arthritis Res Ther Date: 2022-04-29 Impact factor: 5.606
Authors: Thomas Bögl; Franz Mlynek; Markus Himmelsbach; Norbert Sepp; Wolfgang Buchberger; Marija Geroldinger-Simić Journal: Biomedicines Date: 2022-03-04